Physician profile
Jeffrey D Moore
NPI 1023014008
$3,224.18
in general payments reported to CMS, 2019-2025
47 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $453 · 2021: $454 · 2022: $526 · 2023: $340 · 2024: $469 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $229.48 | 2019-2021 | |
| Amgen INC. | $205.76 | 2019-2025 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.49 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $162.13 | 2019-2024 | Wegovy |
| Alphatec Spine, INC | $150.23 | 2020 | |
| Exact Sciences Corporation | $133.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $127.52 | 2021-2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $127.03 | 2019-2024 | Dificid |
| Astellas Pharma US INC | $122.86 | 2019-2023 | Myrbetriq, Veozah |
| Pfizer INC. | $107.15 | 2019-2025 | |
| Dexcom, INC. | $103.40 | 2021-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $96.07 | 2021-2023 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $93.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.98 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.32 | 2022-2025 | Caplyta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.